General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Non-Hodgkin's Lymphoma and Multiple Myeloma
Last updated January 6, 2014
Apprilon (doxycycline monohydrate)
Status:
Negotiations were not pursued
Manufacturer:
Galderma Canada Inc.
Indication:
Rosacea
Last updated December 17, 2013
Votrient (pazopanib hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Metastatic Renal Cell Carcinoma
Last updated December 2, 2013
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Metastatic Renal Cell Carcinoma
Last updated November 22, 2013
Status:
Concluded with an LOI
Manufacturer:
Optimer Pharmaceuticals
Indication:
Clostridium difficile infection
Last updated November 13, 2013
Edarbyclor (azilsartan medoxomil/chlorthalidone)
Status:
Negotiations were not pursued
Manufacturer:
Takeda Canada Inc.
Indication:
Hypertension
Last updated November 12, 2013
Status:
Negotiations were not pursued
Manufacturer:
Takeda Canada Inc.
Indication:
Hypertension
Last updated November 12, 2013
Status:
Negotiations were not pursued
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex (TSC)
Last updated November 1, 2013
Status:
Negotiations were not pursued
Manufacturer:
Valeant Canada
Indication:
Insomnia, short-term treatment
Last updated October 24, 2013
Perjeta/Herceptin (pertuzumab/trastuzumab)
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Metastatic Breast Cancer
Last updated October 18, 2013